(Q40928419)

24 September 2017

title

HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect (English)

1 reference

24 September 2017

1 reference

Yao XJ

1

1 reference

24 September 2017

Kobinger G

2

1 reference

24 September 2017

Dandache S

3

1 reference

24 September 2017

Rougeau N

4

1 reference

24 September 2017

Cohen E

5

1 reference

24 September 2017

publication date

1 September 1999

1 reference

24 September 2017

1 reference

24 September 2017

volume

6

1 reference

24 September 2017

issue

9

1 reference

24 September 2017

page(s)

1590-1599

1 reference

The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Induction of cell differentiation by human immunodeficiency virus 1 vpr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Complementation of integrase function in HIV-1 virions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Targeting of chrolamphenicol acetyltransferase to human immunodeficiency virus particles via Vpr and Vpx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Sensitive reverse transcriptase assay to detect and quantitate human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300988

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3300988

1 reference

Dimensions Publication ID

24 September 2017

1020831977

0 references

1 reference